Prognostic Significance of the Loss of Heterozygosity of in Early-Stage Lung Adenocarcinoma.

Lung cancer is a common disease with a poor prognosis. Genomic alterations involving the gene are common in lung carcinomas, although much is unknown about how different mutations, deletions, and expressions influence the disease course. The first approval of a -directed inhibitor was recently approved by the FDA.

Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy.

Personalised cancer treatment depends on identification of therapeutically relevant biological subgroups of patients for assessing effect of treatment and to discover new therapeutic options. By analyses in heterogeneous patient populations, the effects may be lost in noise. Squamous cell carcinoma of the lung is a major killer worldwide.